Emerging Biopharma

Making early commercial data and analytics decisions for launch cen future-proof their data management.

Sun Pharma’s acquisition of Checkpoint Therapeutics includes Unloxcyt, an FDA-approved anti-PD-L1 therapy for metastatic and locally advanced cutaneous squamous cell carcinoma.

The acquisition is expected to enhance Jazz's oncology portfolio by adding dordaviprone, a novel small molecule therapy in development for H3 K27M-mutant diffuse glioma.

FP008 is designed for patients with solid tumors that have not responded to existing immunotherapies targeting PD-1.

The Alpha Cognition executive discusses recent developments that positively impact the upcoming launch for ZUNVEYL.

The funding, led by existing and new investors, is expected to support Eikon’s efforts to integrate advanced computing, automation, and data science that drives innovation in drug development.

Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights to commercialize the treatment outside of North America.

Valencia will seek to leverage the investment as well as Surek’s leadership experience to drive commercialization of its flagship eCoin system to develop minimally invasive treatments for urinary incontinence.

Led by Bosch Ventures, Applyo Jena’s Series A funding seeks to accelerate the development and commercialization of its advanced pharmaceutical technologies.

Under terms of the deal, Epitopea and Merck will work to identify Cryptigen tumor-specific antigens through Epitopea’s CryptoMap platform.

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five expanding therapeutic areas.

Gene Mack, Gain Therapeutics CEO, provides a look into the future of the company and the use of physics-based artificial intelligence in the drug discovery process.

As part of the funding, Latent Labs aims to leverage generative artificial intelligence to computationally create novel therapeutic molecules, such as antibodies and enzymes, to improve molecular features.

Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve overall survival in patients with advanced of metastatic non-small cell lung cancer who are PD-1 checkpoint inhibitor resistant.

A surge in biotech startup out-licensing deals from the country are paving the way for increased IPO and M&A activities.

The trial, developed in collaboration with Novotech, will specifically target dietary and alcohol-induced overindulgence.

New partnerships aim to expand Teva’s biosimilar portfolio and enhance access to high-cost biologics across key markets.